课题基金 / 基金详情

Development of an antigen-specific nanomedicine for the treatment of primary biliary cirrhosis, a severe autoimmune disease of the liver

Development of an antigen-specific nanomedicine for the treatment of primary biliary cirrhosis, a severe autoimmune disease of the liver
开发用于治疗原发性胆汁性肝硬化(一种严重的自身免疫性肝脏疾病)的抗原特异性纳米药物
批准号:
297029
负责人:
Sokke Umeshappa Channakeshava
金额:
$10.2万
依托单位:
依托单位国家:
加拿大
项目类别:
Fellowship Programs
财政年份:
2013
资助国家:
加拿大
项目状态:
已结题
起止时间:
2013-10-01 至 2015-10-01

项目摘要

项目成果

Sokke Umeshappa Channakeshava的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This proposal is founded on the discovery of a new paradigm in the treatment of autoimmune diseases (caused by the white blood cells of the immune system) of groundbreaking significance. Traditionally, vaccines have been used to expand white blood cells c
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Spring 2024 CIHR-III New Investigator Forum "Connecting and Advancing: Dr. Umeshappa's Elevator Pitch"
  • 批准号:
    495261
  • 项目类别:
  • 资助金额:
    $0.22万
  • 财政年份:
    2023
  • 负责人:
    Sokke Umeshappa Channakeshava
  • 依托单位:
Canada Research Chair - Tier 2
  • 批准号:
    459663
  • 项目类别:
  • 资助金额:
    $43.71万
  • 财政年份:
    2021
  • 负责人:
    Sokke Umeshappa Channakeshava
  • 依托单位:
Visualizing and killing metastasis in liver
  • 批准号:
    243252
  • 项目类别:
    Fellowship Programs
  • 资助金额:
    $3.28万
  • 财政年份:
    2011
  • 负责人:
    Sokke Umeshappa Channakeshava
  • 依托单位:
The critical role of CD4+ Th cells in CD8+ CTL responses and anti-tumor immunity
  • 批准号:
    197120
  • 项目类别:
    Studentship Programs
  • 资助金额:
    $7.29万
  • 财政年份:
    2009
  • 负责人:
    Sokke Umeshappa Channakeshava
  • 依托单位:
海外基金